CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Aveo Pharmaceuticals, Inc. (AVEO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Aveo Pharmaceuticals, Inc. (AVEO)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-08-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
  • 2027-08-15 (est.)Phase 3 · Ficlatuzumabimp 9/10
Pipeline
AssetPhaseIndication
tivozanib (AV-951)Phase 3Advanced Renal Cell Carcinoma
FiclatuzumabPhase 3Metastatic Head-and-neck Squamous-cell Carcinoma
TivozanibPhase 3Renal Cell Carcinoma
Tivozanib hydrochloridePhase 3Carcinoma, Renal Cell
mFOLFOX6Phase 2Colorectal Cancer
AV-299 + gefitinibPhase 2Carcinoma, Non-Small Cell-Lung
Decitabine (BAML-16-001-S5)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AZD5991 (BAML-16-001-S18)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Bleximenib (BAML-16-001-S25/HO181)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Revumenib (BAML-16-001-S26/HO177)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Daunorubicin (BAML-16-001-S1)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Entospletinib (BAML-16-001-S4)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Gilteritinib (BAML-16-001-S8 Group 1)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AG-120 (BAML-16-001-S16)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Decitabine (BAML-16-001-S8 Group 2)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
ZE46-0134 (BAML-16-001-S21 Group 1)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Pevonedistat (BAML-16-001-S9)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
TP-0903 (BAML-16-001-S14)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Cytarabine (BAML-16-001-S25/HO181)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Entospletinib (BAML-16-001-S6)Phase 3Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for AVEO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.